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Importance
Malignant Hyperthermia (MH) is a rare but 
life-threatening, genetic condition that can 
manifest when a patient is exposed to certain 
inhalation agents used in anesthesia as well as 
the depolarizing muscle relaxant 
succinylcholine (Rosenberg, Pollock, 
Schiemann, Bulger, & Stowell, 2015, p. 1). 
MH is an autosomal dominant trait with 
incomplete penetrance that has been found in 
“approximately 1:40,000 adults” (Creech & 
Zhang, 2019, p. 1). The RYR1 gene, which 
encodes for calcium release channels in the 
sarcoplasmic reticulum, is the most prevalent 
gene mutation found in MH patients (Miller et 
al., 2018, p. 945). 
MH can develop during or after a surgical 
procedure and if left untreated, can cause 
major organ system damage and death 
(Seifert, Wahr, Pace, Cochrane, & Bagnola, 
2014, p. 189). Creating awareness of this rare 
genetic condition allows for quicker 
interventions in reversing MH.
Due to the increased awareness, genetic 
testing, and MH protocol, the incidence of 
death due to MH “has decreased in the last 
thirty years” (Rosenberg et al., 2015, p. 13). 
More specifically, MH mortality has been 
reduced from “80% to 1.4%” (Rosenberg et 
al., 2015, p. 13).  The continued awareness 
and research of MH should be maintained to 
effectively decrease the mortality rates of 
MH.
Epidemiology
• Incidence of MH episodes (Creech & Zhang, 
2019, p. 1):
• 1:40,000 in adults
• 1:15,000 in pediatrics 
• On average, patients require exposure to three 
anesthetic events before a triggering event 
(Rosenberg et al., 2015, p. 2).
• All ethnic groups are affected (Rosenberg et 
al., 2015, p. 2).
• Reactions develop more frequently in males 
than in females (Rosenberg et al., 2015, p. 2).
• The average age of occurrence is 18.3 years 
(Rosenberg et al., 2015, p. 2).
• Three genes have been associated with MH 
susceptibility (Miller et al., 2018, p. 945):
• RYR1 gene
• CACNA1S gene
• STAC3 gene
• MH genes are inherited by an autosomal 
dominant pattern with incomplete penetrance 
(Creech & Zhang, 2019, p. 1). 
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Figure 1. Signs and symptoms of MH 
(Rosenberg et al., 2015, pp. 2-3)
• MH may occur anytime during anesthesia 
administration or within one hour of 
discontinuation of volatile agents (Rosenberg 
et al., 2015, p. 2).
• Some people may only exhibit a few 
symptoms, making MH difficult to diagnose 
(Mullins, 2018, p. 538).
Current Research
Additional Sources
Figure 3.  Triggering agents of MH mechanism of action (Klingler et al., 2014, p. 3) 
1. Acetylcholine binds to postsynaptic nicotinic 
acetylcholine receptors (nAChR) located on the 
sarcolemma (skeletal muscle cell membrane) 
(Mullins, 2018, p. 583).
2. Activation of nonselective cation channels 
depolarize the sarcolemma and the action 
potential travels down the transverse tubule (t-
tubule) system (Mullins, 2018, p. 583).
3. L-type voltage-gated calcium (Cav1.1) channels 
located in the t-tubule undergo a conformational 
change due to depolarization. Cav1.1 channels 
signal the type 1 ryanodine receptors (RyR1) to 
open and release calcium (Ca2+) from the 
sarcoplasmic reticulum (SR) (Mullins, 2018, p. 
583).
4. The influx of extracellular Ca2+ through Cav1.1 
channels and intracellular release of Ca2+ from 
the SR activate muscle contraction by Ca2+ 
binding to troponin (Mullins, 2018, p. 583).
Figure 2. Excitation-contraction coupling process 
(Excitation-contraction coupling, 2019) 
• Three genetic mutations are linked to MH susceptibility 
(Miller et al., 2018, p. 945):
• RyR1 gene: encodes the channel that releases Ca2+
from the SR.
• CACNA1S gene: encodes the main subunit of the t-
tubule voltage sensor.
• STAC3 gene: encodes a protein responsible for 
directing the voltage sensor into the correct t-tubule 
location and a direct role in excitation-contraction 
coupling.
• Signs and symptoms of MH are related to the 
uncontrolled release of intracellular Ca2+ from the SR 
(Rosenberg et al., 2015, p. 4).
• Increased intracellular Ca2+ causes abnormal skeletal 
muscle metabolism manifesting as (Rosenberg et al., 
2015, p. 4):
• Muscle contraction
• Increased oxygen consumption
• Increased carbon dioxide production
• ATP hydrolysis
• Heat production 
• Hypermetabolic state: leads to respiratory and 
metabolic acidosis due to the rapid consumption of 
energy stores and ATP (Rosenberg et al., 2015, p. 2).
• Hyperthermia: a dramatic increase in core temperature 
(1-2 ˚C every five minutes) related to the 
hypermetabolic state (Rosenberg et al., 2015, p. 2).
• DIC: associated with end-stage organ failure and 
prolonged hyperthermia (Litman, 2019).
• Magnesium (Mg2+) in MH treatment (Choi, 
Koenig, & Launikonis, 2017).
• The research concluded that the 
administration of dantrolene in the 
presence of higher levels of Mg2+ is more 
effective than normal, resting Mg2+ levels.
• Dantrolene increases the affinity of the 
RyR1 channels for free Mg2+.
• Free Mg2+ helps suppress Ca2+ release 
from the RyR1 channels. Thus, decreasing 
intracellular Ca2+ accumulation in skeletal 
muscles.
• Treatment (Seifert et al., 2014, pp. 190-196):
• Discontinuation of trigger agents
• Increase oxygenation and hyperventilate 
• Dantrolene 2.5 mg/kg every five minutes
• Cooling measures
• Treat electrolyte disturbance
• Treat rhythm disturbances 
• Monitor for recrudescence (24 hours)
• Dantrolene is the only drug known to treat MH 
(Rosenberg et al., 2015, p. 10):
• Binds to specific sites on the RyR1 protein 
and reduces channel activity.
• Available in:
• Dantrium (20 mg vial), which requires 
60 mL of sterile water to prepare.
• Ryanodex (250 mg ampoule), which 
requires 5 mL of sterile water to 
prepare.
Clinical Resources
• Preventative measures (Rosenberg et al., 2015, 
pp. 11-12):
• Preoperative assessment for a history of MH
• Awareness of community genetics.
• Clusters of MH cases located in 
Wisconsin, Nebraska, West Virginia, 
and Michigan (Mullins, 2018, p. 583).
• Patients with any form of muscle disorder 
should receive extra anesthesia caution.
• Patients undergoing general anesthesia 
should have core temperature monitoring.
• Total intravenous anesthesia should be 
considered for MH suspectable patients.
• Awareness of facility MH protocol.
• MH Carts (Seifert et al., 2014, p. 194):
• Available in some facilities.
• Contains all the necessary supplies to 
manage an MH crisis.
• MHAUS Hotline (Seifert et al., 2014, p. 194):
• (800) 644-9737
• National hotline is available for instruction.
Despite the rarity of MH, the genetic 
condition must be thoroughly understood by 
all health care professionals that interact with 
patients who are exposed to anesthetic gases 
and succinylcholine. The providers must be 
vigilant to certain signs and symptoms and be 
ready to respond quickly.
MH crisis requires specific interventions 
within certain time frames. The awareness of 
MH protocol and treatment allows providers to 
deliver optimal care in emergencies. Team 
training, simulation, and case studies are 
important in preparing health care members 
for an MH emergency.
By understanding the pathophysiological 
process of MH, providers can differentiate 
symptoms of MH from other pathologies. 
Comprehension of MH at the cellular level 
aids in the knowledge of MH treatment 
interventions. 
• Triggering agents for MH (Seifert et al., 2014, p. 
192):
• Volatile anesthetics:
• Desflurane
• Enflurane
• Isoflurane
• Sevoflurane
• Depolarizing neuromuscular blockers (NMB):
• Succinylcholine
• Triggering agents' effect on Ca2+ release (Klingler 
et al., 2014, p.4):
• Volatile anesthetics
• Act directly on RyR1 channels to stimulate 
the release of Ca2+  from the SR.
• Succinylcholine 
• Acts indirectly by activating the nAChR
resulting in continuous cation influx.
• Cation influx causes continuous 
depolarization which allows action 
potentials to activate the Cav1.1 channels 
leading to RyR1 channel activation.
• Muscle rigidity: sustained contracture related to the 
increased level of intracellular Ca2+ in skeletal 
muscles (Litman, 2019).
• Rhabdomyolysis: the breakdown of skeletal muscle 
results in life-threatening hyperkalemia and 
myoglobinuria (Litman, 2019).
• Cardiac arrhythmias: frequently develop due to 
acute hyperkalemia (ie. ventricular ectopy, 
tachycardia or fibrillation) (Litman, 2019).
Case Report
(Mullins, 2018)
J.M., a 24-year-old female, presented for 
an elective bilateral breast reduction surgery. 
The preoperative evaluation reported no 
abnormalities, but J.M. was adopted so there 
was no known family medical history. 
Anesthesia induction was performed, and vital 
signs remained stable. J.M. was mechanically 
ventilated and maintained with desflurane, 
fentanyl, and vecuronium.
Twenty-five minutes after induction, J.M. 
started to exhibit masseter spasm and the 
surgeon noted muscle rigidity. 
Simultaneously, J.M. became tachycardiac, 
hypertensive, dark color urine was noted, and 
her end-tidal carbon dioxide (EtCO2) rose to 
58 mmHg. Her forehead temperature probe 
remained constant at 36.9 ˚C. The anesthesia 
provider suspected the onset of MH and called 
for additional staff members. 
